Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue

Table 1 Summary of baseline characteristics of 465 study patients who were treated with either lamivudine or tenofovir disoproxil fumurate enrolled in the Canadian hepatitis B virus network

	LAM treated (n = 166)	TDF treated (n = 299)	P value
Age (yr)	51.6 (49.7-53.6)	47.2 (45.7-48.6)	< 0.001c
Male sex	58.4% (97/166)	64.9% (194/299)	0.194
Ethnicity (LAM 88%, n = 147/166 known, TDF, 88% n = 266/299 known)
Asian	85.0% (125/147)	82.7% (220/266)	0.582
Black/African/Caribbean	5.4% (8/147)	10.9% (29/266)	0.072
White	6.8% (10/147)	5.6% (15/266)	0.669
Other	2.7% (4/147)	0.4% (1/266)	0.056
Laboratory
HBeAg positive	24.1% (26/108)	39.9% (99/248)	0.004b
HBV DNA (log10 IU/mL)	7.5 (6.7-7.7) n = 149	7.6 (7.5-7.8) n = 269	0.260
ALT (IU/mL)	74.3 (62.0-86.7) n = 139	87.8 (76.8-98.7) n = 264	0.225
Mean ALT × ULN	2.7 (2.1-3.3) n = 139	3.7 (2.9-4.4) n = 264	0.077
Fibrosis (baseline)
Mean Baseline Fibrosis (kPa)	8.3 (7.2-9.5) n = 100	11.2 (9.9-12.4) n = 184	0.003b
F0-F1 Fibrosis (< 7.3 kPa)	53% (53/100)	37.5% (69/184)	0.013a
F2-F3 Fibrosis (7.3-9.5 kPa)	25% (25/100)	16.9% (31/184)	0.119
F4 Fibrosis (> 9.5 kPa)	22% (22/100)	45.7% (84/184)	< 0.001c

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

Continuous data are shown as mean (95% CI, n known). Categorical data are shown as mean % (n/n known). For continuous data, a two-tailed t test was used. Whereas Fisher’s exact test was used for categorical data. LAM: Lamivudine; TDF: Tenofovir disoproxil fumarate; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; ULN: Upper limit of normal.